問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Sin-Lau Medical Foundation, the Presbyterian Church in Taiwan

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 701Tainan CityTainan East

Recruiting Trial

1Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

8Cases

2021-05-20 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2004-04-01 - 2005-04-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2019-08-19 - 2024-04-30

Phase III

Completed
A 12-week phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once monthly subcutaneous erenumab 70 mg in adult chronic migraine patients

  • Condition/Disease

    Chronic Migraine

  • Test Drug

    AMG334 (erenumab)

Participate Sites
9Sites

Recruiting2Sites

Terminated7Sites

林剛旭
China Medical University Hospital

2016-02-01 - 2020-04-02

Phase III

A Phase 3, randomized, double-blind, placebo-controlled study to evaluate LY2951742 in patients with chronic migraine — the REGAIN trial.

  • Condition/Disease

    Chronic migraine

  • Test Drug

    LY2951742

Participate Sites
5Sites

Terminated5Sites

2008-03-06 - 2009-02-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-02-01 - 2018-06-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    LY2951742

Participate Sites
6Sites

Terminated6Sites

2018-02-01 - 2020-05-30

Phase III

A 12-week double-blind, randomized, multi-center study comparing the efficacy and safety of once monthly subcutaneous AMG 334 against placebo in adult episodic migraine patients (EMPOwER)

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    AMG334

Participate Sites
9Sites

Terminated8Sites

Study ended1Sites

林剛旭
China Medical University Hospital

羅榮昇
Linkou Chang Gung Medical Foundation

2019-09-01 - 2022-07-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB